Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.

Date Event
May 7, 2007 Protalix BioTherapeutics to Present at the BIO International Convention
June 4, 2007 Protalix BioTherapeutics Appoints Dr. Ernest Beutler to its Scientific Advisory Board
June 20, 2007 Protalix BioTherapeutics Plans to Offer Common Stock to the Public
June 26, 2007 Protalix BioTherapeutics Added to Russell 3000® Index
July 13, 2007 Protalix BioTherapeutics, Inc. Receives Special Protocol Assessment Approval from
FDA for its Phase III Clinical Study of prGCD
August 6, 2007 Protalix BioTherapeutics Appoints Prof. Aaron Ciechanover
a Laureate of the Nobel Prize in Chemistry, to its Scientific Advisory Board
August 8, 2007 Protalix BioTherapeutics Signs Agreement to License Acetylcholinestrase
Development Technology
August 27, 2007 Protalix BioTherapeutics Treats First Patient in
Phase III Clinical Trial of prGCD
September 19, 2007 Protalix BioTherapeutics to Present at
UBS Global Life Sciences Conference
October 7, 2007 Protalix BioTherapeutics Announces Public Offering of Common Stock
October 24, 2007 Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
November 2, 2007 Protalix BioTherapeutics to Present at
CIBC World Markets 18th Annual Healthcare Conference
November 29, 2007 Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
December 3, 2007 Protalix BioTherapeutics´ prGCD Named One of the Five Most Promising
Drugs Entering Phase III Trials by Thomson Scientific

© 2007 Protalix Biotherapeutics. All Rights Reserved.